Your browser doesn't support javascript.
loading
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
Smith, Amanda M; Dun, Matthew D; Lee, Erwin M; Harrison, Celeste; Kahl, Richard; Flanagan, Hayley; Panicker, Nikita; Mashkani, Baratali; Don, Anthony S; Morris, Jonathan; Toop, Hamish; Lock, Richard B; Powell, Jason A; Thomas, Daniel; Guthridge, Mark A; Moore, Andrew; Ashman, Leonie K; Skelding, Kathryn A; Enjeti, Anoop; Verrills, Nicole M.
Affiliation
  • Smith AM; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.
  • Dun MD; Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
  • Lee EM; Current address: The University of Queensland Diamantina Institute, Woolloongabba, Queensland, Australia.
  • Harrison C; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.
  • Kahl R; Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
  • Flanagan H; Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, Sydney, New South Wales, Australia.
  • Panicker N; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.
  • Mashkani B; Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
  • Don AS; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.
  • Morris J; Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
  • Toop H; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.
  • Lock RB; Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
  • Powell JA; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.
  • Thomas D; Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
  • Guthridge MA; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia.
  • Moore A; Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
  • Ashman LK; Current address: Department of Medical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Skelding KA; Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
  • Enjeti A; School of Chemistry, University of New South Wales, Sydney, New South Wales, Australia.
  • Verrills NM; School of Chemistry, University of New South Wales, Sydney, New South Wales, Australia.
Oncotarget ; 7(30): 47465-47478, 2016 Jul 26.
Article in En | MEDLINE | ID: mdl-27329844
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Protein Kinase Inhibitors / Fms-Like Tyrosine Kinase 3 / Protein Phosphatase 2 Limits: Animals / Humans Language: En Journal: Oncotarget Year: 2016 Document type: Article Affiliation country: Australia
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Protein Kinase Inhibitors / Fms-Like Tyrosine Kinase 3 / Protein Phosphatase 2 Limits: Animals / Humans Language: En Journal: Oncotarget Year: 2016 Document type: Article Affiliation country: Australia